Cyclosporine - cyclosporine microemulsion

ApprovedCompleted

2 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Maintenance Liver Transplant Patients With New Onset Diabetes

Conditions

Maintenance Liver Transplant Patients With New Onset Diabetes

Trial Timeline

Feb 1, 2004 → Dec 1, 2005

NCT ID

NCT00171717

About Cyclosporine - cyclosporine microemulsion

Cyclosporine - cyclosporine microemulsion is a approved stage product being developed by Novartis for Maintenance Liver Transplant Patients With New Onset Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT00171717. Target conditions include Maintenance Liver Transplant Patients With New Onset Diabetes.

What happened to similar drugs?

6 of 20 similar drugs in Maintenance Liver Transplant Patients With New Onset Diabetes were approved

Approved (6) Terminated (2) Active (12)

✅Zolpidem MR + EstazolamAstellas PharmaApproved

🔄zolpidem MR + nitrazepam + placeboAstellas PharmaPhase 3

🔄FK199B + ZolpidemAstellas PharmaPhase 3

✅Zolpidem MR + Zolpidem IRAstellas PharmaApproved

🔄Zolpidem MR + ZolpidemAstellas PharmaPhase 3

🔄Lemborexant + PlaceboEisaiPhase 3

✅Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00171717	Approved	Completed	Feb 1, 2004	Dec 1, 2005	Maintenance Liver Transplant Patients With New Onset Diabetes

Competing Products

20 competing products in Maintenance Liver Transplant Patients With New Onset Diabetes

See all competitors

Product	Company	Stage	Hype Score
LY2422347 + placebo	Eli Lilly	Phase 2	35
LY2624803 - Solution + LY2624803 - Capsule + Placebo - Solution + Placebo - Capsule	Eli Lilly	Phase 1	29
Zolpidem MR + Estazolam	Astellas Pharma	Approved	43
zolpidem MR + nitrazepam + placebo	Astellas Pharma	Phase 3	40
FK199B + Zolpidem	Astellas Pharma	Phase 3	40
ASP7991	Astellas Pharma	Phase 1	29
Graceptor®	Astellas Pharma	Pre-clinical	26
Zolpidem MR + Zolpidem IR	Astellas Pharma	Approved	43
Zolpidem MR + Zolpidem	Astellas Pharma	Phase 3	40
Lemborexant	Eisai	Phase 2	35
Lemborexant + Placebo	Eisai	Phase 3	40
Lemborexant	Eisai	Pre-clinical	26
Eszopiclone + Fluoxetine + Placebo	Sumitomo Pharma	Approved	43
Org 50081 + Org 50081 + Placebo + zopiclone	Merck	Phase 1	29
esmirtazapine	Merck	Phase 3	32
Esmirtazapine	Merck	Phase 3	40
Suvorexant + Placebo	Merck	Phase 3	40
Esmirtazapine + Placebo	Merck	Phase 3	40
Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetil	Novartis	Approved	43
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Approved	43